Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 13.40
- Piotroski Score 4.00
- Grade Buy
- Symbol (MRUS)
- Company Merus N.V.
- Price $50.85
- Changes Percentage (-0.74%)
- Change -$0.38
- Day Low $48.42
- Day High $51.20
- Year High $61.61
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $85.00
- High Stock Price Target $99.00
- Low Stock Price Target $30.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.73
- Trailing P/E Ratio -19.38
- Forward P/E Ratio -19.38
- P/E Growth -19.38
- Net Income $-154,939,000
Income Statement
Quarterly
Annual
Latest News of MRUS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Merus NV (MRUS): Short Seller Sentiment is Bearish on This Cancer Stock
The article discusses the state of cancer stocks in the market, focusing on Merus NV (NASDAQ:MRUS). It highlights the growth of the oncology sector, the development of cancer treatments, and the poten...
By Yahoo! Finance | 1 month ago -
Insider Sale: Vitalii Obishchenko Sells 55,000 Shares of SEMrush Holdings Inc (SEMR)
Vitalii Obishchenko, COO of SEMrush Holdings Inc, sold 55,000 shares, now owning 848,923 shares. SEMrush is a global company offering content marketing and SEO tools....
By Yahoo! Finance | 1 month ago -
Merus NV (MRUS): Top ADR Stock According to Hedge Funds
The article discusses the importance of diversifying investment portfolios with ADR stocks, focusing on Merus NV (NASDAQ:MRUS) as one of the top 10 ADR stocks to buy according to hedge funds....
By Yahoo! Finance | 2 months ago
